In palbociclib and other CDK4/6 inhibitor trials, improved patient outcomes were observed (5), resulting in CDK4/6 inhibitors plus ET being the standard of care for advanced hormone receptor–positive (HR+) breast cancer treatment. This evidence concerns the gene CDK4 and breast cancer.